100 paticipants included in the SHIVA cohort!

SHIVA cohort reaches 100 participants! Congratulations to the SHIVA clinical team of the Bordeaux and Paris Hospitals for their efforts and investment in this great achievement!

📣 The study is still recruiting 60+ patients with high blood pressure and memory complaints. If you are interested in participating, please send us a message here!

The Aim:

Include 400 patients to explore the relation of brain and retinal microvasculature image characteristics (imaging biomarkers), as well as molecular biomarkers derived from blood, with presence or absence of extensive cSVD and with cognitive and other clinical characteristics in two groups of 200 patients 60+ years of age:

• The Control group will consist of 200 patients with little or no white matter hyperintensities on brain MRI (no or minor MRI features of cSVD)
• The MPAC group will include 200 patients with moderate to severe white matter hyperintensities (MRI features of extensive cSVD).

This will create a unique deeply characterized resource for epidemiological and mechanistic investigations of cSVD, which can also serve as a pilot setting to test the trajectories and requirements for individualized patient care of cSVD patients.

Prof. Stéphanie Debette

The combination of retinal microvascular measurements using innovative multimodal imaging is entirely novel to our knowledge. In the context of the RHU SHIVA program, the same retinal microvascular imaging protocol is being implemented in 400 young adults, which will provide insight into trajectories of these retinal biomarkers across the adult lifespan (SHIVA-Share cohort).

For the molecular biomarkers, the SHIVA cohort will focus in particular on validation of genomic, epigenomic, transcriptomic, proteomic, and metabolomic biomarkers for cSVD identified through secondary use of large existing cohort studies in the general population, in persons with memory complaints, and in collaboration with other cohorts with the Cohorts for Heart and Aging Research in Genomic Epidemiology consortium, also as part of the RHU SHIVA program.